---

IUD - Intrauterine Device

---

Types

1. Copper IUD (ParaGard T380A)

• Contains no hormones
• Works by creating a sterile inflammatory reaction in the endometrium that is essentially spermicidal - it impairs sperm motility and viability, preventing fertilization
• Approved for up to 10 years of use
• Also used as emergency contraception - effective up to 5-7 days after unprotected intercourse, with a 99% reduction in pregnancy risk
• Failure rate: ~0.08%

2. Levonorgestrel IUD (LNG-IUS) - e.g., Mirena, Kyleena, Liletta

• Releases the progestin levonorgestrel locally
• Mechanisms of action:
  • Thickens cervical mucus (blocks sperm entry)
  • Thins the endometrial lining
  • Partially suppresses ovulation in some cycles
• Different sizes and hormone doses available (52 mg, 19.5 mg, etc.)
• Approved for 3-8 years depending on the brand
• Failure rate: ~0.02% (lowest of any contraceptive)
• Bonus benefit: reduces heavy menstrual bleeding - used to treat fibroids and endometriosis-related heavy periods

---

Indications

• Long-term contraception (can be used even in nulliparous women - nulliparity is no longer a contraindication)
• Emergency contraception (copper IUD)
• Treatment of heavy menstrual bleeding (LNG-IUS)
• Safe for women who cannot use estrogen-containing contraceptives (e.g., hypertension, migraines with aura, history of DVT)

---

Contraindications

---

Insertion

• Optimally inserted in the late follicular phase (days 5-10 of the cycle) to reduce expulsion risk
• Pre-insertion: Pap smear, pelvic exam, STI screening
• Pre-medication: ibuprofen 600-800 mg, 45-60 minutes before, to reduce cramping
• After insertion, threads are cut to 2-3 cm beyond the cervical os
• Effective immediately upon insertion

---

Common Side Effects

• Copper IUD: Heavier, more painful periods (especially in the first few months)
• LNG-IUS: Irregular spotting initially, then often leads to lighter periods or amenorrhea; ovarian cysts (enlarged follicles) in ~12% of users, usually self-limiting
• Both: Cramping and spotting for a few days to weeks post-insertion

---

Complications

---

Common Myths Clarified (per textbook)

• IUDs are not abortifacients - they prevent fertilization, not implantation
• IUDs do not increase ectopic pregnancy risk overall - they prevent all pregnancies; however, if a pregnancy does occur with an IUD in place, the proportion that are ectopic is higher
• IUDs do not inherently increase PID risk - the insertion procedure carries a small transient risk, but not the device itself

---

Removal & Return to Fertility

• Can be removed at any time
• Fertility returns rapidly after removal of both copper and LNG-IUS devices
• Pregnancy can be attempted immediately after removal

---

---

Pilot Plant Scale-Up Techniques

Industrial Pharmacy II - BP702T | Dr. Ketan Ranch

---

1. What is a Pilot Plant?

• A drug developed at lab scale (proven for efficacy, safety, stability) must be produced at large scale for commercial availability.
• The lab environment differs greatly from the manufacturing floor - equipment type, capacity, operating principles, and process conditions are all different.
• The concept of a pilot plant emerged to study and tackle these product-transfer problems.

---

2. Pilot Scale vs. Scale-Up

• Pilot scale: Manufacturing of a drug product by a procedure fully representative of and simulating that used for full manufacturing scale.
• Scale-up: The process of increasing batch size or applying the same process to different output volumes.
  • In mixing, scale-up = increasing batch volume
  • In tableting, scale-up = increasing output by increasing speed
• A process may be perfect at lab or pilot scale but fail quality tests at production scale - because processes are scale-dependent.

---

3. Why Conduct Pilot Plant Studies?

---

4. Uses of a Pilot Plant

• Evaluate lab study results; make corrections and improvements
• Produce small quantities for sensory, chemical, microbiological testing
• Supply samples for market testing or potential customers
• Conduct shelf-life and storage stability studies
• Determine if salable by-products or waste streams exist
• Provide data for go/no-go decisions on full-scale production
• Help design or modify a full-size plant

---

5. Functions of a Pilot Plant

1. Review product formula - assess ability to withstand batch scale changes
2. Select, approve, and validate raw material specifications
3. Select and validate processing equipment
4. Evaluate and validate process and production controls
5. Transfer developed process to the shop floor for routine manufacturing

---

6. Differences: Small Scale vs. Large Scale

---

7. Development Process for Formulations (Batch Stages)

---

8. Scientific Scale-Up: Similarity Principles

A. Geometric Similarity

• Same shape and dimensional proportions across scales
• Key: constant aspect ratio (pan length:diameter), proportional baffles, constant pan load-to-volume ratio
• Parameters: vessel diameter, impeller diameter, baffle widths

B. Kinematic Similarity

• Same velocity ratios at corresponding points across scales
• Tablet velocity and spray kinetics should remain the same
• Spray location along cascading bed length must be maintained constant

C. Dynamic Similarity

• Same force ratios (inertial, gravitational, viscous, surface tension) at corresponding points
• Key dimensionless number: Froude number (Fr) = ratio of inertial to gravitational forces
• If dynamic similarity is achieved, geometric and kinematic similarity are also met

---

9. Pilot Plant Design

Three Key Strategic Objectives

1. Formulation & Process Development
2. Clinical Supply Manufacture
3. Technology Evaluation, Scale-up & Transfer

Key Attributes for Success

• cGMP compliance + flexible, highly trained staff
• Equipment for multiple dosage forms at multiple scales
• Same operating principles as production equipment
• Portable, multipurpose rooms
• Restricted and regulated personnel/material flow
• Low maintenance and operating costs

Validation Pathway

---

10. Pilot Plant Operations (Organizational Aspects)

A. Organizational Structures

B. Staff Qualifications

• Strong theoretical knowledge of pharmaceutics + practical industry experience
• Good communication skills (written and verbal)
• Interpersonal skills
• Understanding of both formulator's intent and production personnel's perspective

C. Training (3 Types)

1. Initial training - for new employees; certifies skill level attained
2. Reinforcement training - for already-trained staff; reinforces acquired skills
3. Remedial training - corrects identified skill deficiencies

---

11. Pilot Plant Activities

1. Formula review - understand each ingredient's role in the final product
2. Raw material selection - specs for particle size, bulk density, flow, solubility, morphology, etc.; evaluate material from multiple suppliers
3. Equipment selection - choose most economical, efficient, simplest equipment based on known processing characteristics
4. Scale-up studies - evaluate unit operations (milling, mixing, heating, drying, sterilization, compaction, filling)
5. Documentation & Technology Transfer

Key Documents Produced

• Lab notebooks (initial development batches)
• Scale-up reports (data collected during scale-up)
• Validation protocol and report
• Master Manufacturing Instructions containing:
  • Weighing sheets (batch size, quantities)
  • Stepwise manufacturing instructions for each unit operation
  • Specifications for mixing times/speeds, heating/cooling rates, temperatures
  • Sampling time points and procedures

---

12. Design and Layout of the Pilot Plant

A. Floor Space

• Subdivided by dosage form type (solids, liquids, semisolids, steriles)
• Space for routine equipment + portable equipment + dedicated cleaning area
• Equipment should be portable and stored in small areas when not in use

B. Testing Facility

• Weighing balance, moisture balance, pH meter, friability tester, disintegration equipment, viscometer, microscope, particle size analyzer

C. Storage

• API and excipients, in-process materials, finished bulk, experimental batch materials, retained samples, stability samples, bulk packaging materials

D. Documentation and Administration

• Adjacent office space, isolated from work area; computer terminals for data entry

E. Material and Personnel Flow

• Controlled access for clinical supply materials
• Special arrangements for potent compounds (airlocks, gowning areas, isolated sampling chambers)
• Flammable solvent areas with special arrangements
• Restricted dock access for delivery/shipping personnel
• Gowning, locker, shower facilities sized by anticipated staff

---

13. Construction Standards

• Floors: High-density concrete; static-dissipative flooring for flammable areas
• Walls: Enamel cement finish with or without concrete masonry
• Joints: Radial joints at wall/ceiling/floor junctions for easy cleaning
• Doors: Metal/fiberglass, easy to clean doorframes
• Lighting: Washable fixtures with adequate process area lighting
• Floor drains: With waste collection for treatment or incineration

---

14. Building Systems and Utilities

---

15. Safety and Environmental Considerations

Environmental Discharges

• Atmospheric discharges (incinerators, scrubbers, dust collectors) must comply with guidelines
• Highly potent/toxic compounds: wastewater must be isolated and pre-treated

Explosion Prevention

• Blow-off explosion venting panels are the most common approach
• Pharmaceutical dusts in sufficient airborne concentration can propagate flames - special ventilation, grounding, and dispensing methods required

Special Materials

---

16. Scale-Up by Dosage Form

---

A. SOLID DOSAGE FORMS

i. Mixing and Blending

• Objective: produce a homogeneous blend - inadequate mixing causes high/low potency pockets
• Blending mechanisms: Convection (bulk particle movement), Dispersion (random particle motion), Shear (breaks agglomerates)
• Critical factors:
  • Particle size distribution, bulk density, cohesiveness
  • Blender load (do not exceed 70-75% capacity)
  • Blending speed and time
  • Geometry, size, symmetry of blender (asymmetric = greater mixing efficiency, e.g., slant cone, offset V-blender)
• De-mixing prevention: uniform particle size, larger granule size, improved surface cohesiveness, minimize transfer steps, control powder drop height, reduce flow rate

ii. Wet Granulation

1. Improve flow of cohesive/sticky materials
2. Improve compressibility
3. Change particle size distribution for better binding
4. Uniformly disperse low-dose potent drugs

iii. Drying

1. FBD capacity (bowl height:diameter ratio)
2. Fluidized velocity and air volume
3. Ratio of drying capacity to granule volume
4. Inlet air temperature
5. Inlet air humidity
6. Granule bed temperature and exhaust air temperature
7. Particle size of blend
8. Quantity of blend

iv. Particle Sizing

• Critical for: weight uniformity, content uniformity, color distribution
• Too large particles → uneven die cavity filling → weight variation
• Too many fines → flow problems → weight variation
• Sieve analysis is the standard method for particle size distribution profiling
• Equipment:
  • Oscillating granulator - for soft agglomerates; risk of metal contamination from screen wear
  • Hammer mill/multi mill - controlled by feed rate, screen size, speed, blade type; low metal contamination risk
  • Vibrosifter/turbosifter - no metal contact, minimal dust, negligible milling action; best for minimal size reduction

v. Direct Compression

• No granulating solution needed - saves time and energy
• Critical: reproducible uniform drug distribution batch to batch
• Key factors:
  1. Order of addition (low-dose API sandwiched between excipients; geometric mixing for very low doses)
  2. Blender load (overloading causes content uniformity problems)
  3. Mixing time (increase or decrease based on uniformity data)
  4. Mixing action (determined by mixer mechanics)
  5. Auxiliary equipment for difficult-to-disperse ingredients

vi. Dry Granulation

• Applies force to densify powder without liquid binders
• Two methods:
  1. Slugging - uses tablet machine at high pressure to form compressed slugs; slower speed = longer dwell time
  2. Roller compaction (e.g., Chilsonator) - powder passed between two high-pressure rollers; ideal for low-density materials
• After compaction: slugs broken down by hammer mill or oscillating granulator
• Scale-up considerations:
  • Machine speed (high speed = problems achieving slug hardness)
  • Lubricant levels (excess = hydrophobic coating, affects hardness and dissolution)
  • Process length (heat build-up affects stability and labile drugs)
  • Abrasive materials (generate heat in long-run batches)

vii. Compression (Tableting)

• Goal: reproducible compression on high-speed machines without affecting quality
• Controlled by validation protocol
• Parameters monitored:
  • Instrument: dwell time, compression force, roller pressure, roller speed
  • Formulation: dissolution, weight uniformity, hardness uniformity
• Common problems during scale-up: picking, lamination, chipping, cracking (caused by altered compression times and ejection forces on different machines)
• Key variables: raw material characteristics, lubricant level (over-blending = soft tablets, poor dissolution), machine type/speed, tooling design, feed frame settings

viii. Tablet Coating

• Core tablet: must be hard; avoid sharp edges, flat surfaces, deep engravings; hydrophobic cores need formulation modification
• Coating material: ingredients, solvents, rheology, tackiness
• Coating process variables:
  • Pan design - use appropriate baffles to reduce chipping/abrasion; redistribute tablet load weight
  • Nozzle type (airless vs. air atomizing): affects liquid flow rate, atomizing pressure
  • Airflow: high airflow = fine spray but more turbulence and spray-drying effect
  • Spray pattern (continuous vs. intermittent): intermittent must be timed to prevent dry tablet abrasion
  • Number of spray guns
  • Gun-to-tablet-bed distance

ix. Hard Gelatin Capsules (Encapsulation)

• Granule characteristics: bulk density variation, powder flow, compressibility, lubricant distribution
  • Poor flow → weight variation
  • Moisture → flow problems and sticking
• Lubricant effects: inadequate = plug sticking; over-lubrication = soft plugs, delayed disintegration/dissolution
• Encapsulation equipment: two filling principles:
  1. Slug formation in a dosator
  2. Compact formation in a die plate using tamping pins
• Environmental control: recommended storage for empty shells = 15-25°C, 35-65% RH (minimizes moisture absorption; high humidity causes shell swelling)

---

B. LIQUID DOSAGE FORMS

i. Solutions (Non-Parenteral)

• Design of mixing vessels, size and shape of mixers, impeller shape and location
• Rate and extent of mixing, liquid flow properties
• Key considerations: liquid transfer systems, filtration monitoring (selective removal must be validated), sanitary non-reactive materials for all tanks, pipes, and mills

ii. Suspensions

• Equipment selection: type/size of mixers, mills, pumps based on viscosity and batch size
• Addition of suspending agent: lab-scale vortex addition vs. production-scale vibrating feed systems
• Sticky/clumping materials: use powder eductors or pre-make slurry of suspending agent
• API dispersion: easily wettable APIs - simple addition; difficult-to-wet/agglomerating APIs - use wetting agents, high-shear mixing, or pre-blend with surfactants in high-shear powder blender
• Air entrapment removal: optimize mixing speed, modify vessel design, use vacuum equipment
• Particulate removal: filter through appropriate mesh screen before filling; mesh size must remove foreign particles but not filter out API
• Filling: continuously mix or recirculate during transfer to prevent sedimentation

iii. Emulsions

• Mixing equipment, homogenizing equipment, temperature control, filters, transfer pumps, filling equipment
• Air and particulate removal: same as suspensions

iv. Parenterals

• Weighing/dispensing: strict GMP at every stage
• Liquid mixing: occurs at three scales:
  • Bulk: transport/bulk diffusion
  • Microscopic: eddy currents create local shear
  • Molecular: final blending by molecular diffusion
  • Large-scale mixing depends on flow and must be monitored
• Other equipment: sterilization, filtration, liquid transfer pumps, packaging must all be scalable

---

C. SEMISOLID PRODUCTS (Pastes, Gels, Ointments, Creams)

• Emulsifying equipment selection: emulsification of two phases + API dispersion is the most critical unit operation
• Mixing equipment: different from liquids due to high viscosity; must effectively move semisolid mass; variable speed mixing; colloid mills and sonic homogenizers used for large scale
  • Colloid mill: fixed stator + high-speed rotor; adjustable gap; milling by physical action + centrifugal force
  • Sonic homogenizer: rapidly vibrating vanes break liquid system into small droplets
• Transfer pumps: must move viscous material without excessive shear or air incorporation; selection based on viscosity, pumping rate, product compatibility, pressure required
• Temperature control: specific temperatures required for mixing oil/water phases, homogenization, API addition, product transfer
  • Poor temp control → wide viscosity ranges
  • For poorly soluble drugs: improper temp → particle size changes, polymorphic transformation, recrystallization → gritty product or poor stability

---

D. SUPPOSITORIES

• Vessel design: jacketed vessels to avoid overheating; monitor jacket temp and molten content temp; high shear mixing to break agglomerates
• Temperature monitoring: critical to prevent settling of suspended material
  • Filling temp too high (much above congealing point) → hole forms in center upon cooling (excessive contraction)
  • Filling temp too low → clogs transfer lines and nozzles
• Order of addition: high-melting-point components first, lower-melting ingredients added once first batch is molten
• Viscosity: filling should occur just above solidification point
• Material transfer: heated transfer lines to avoid choking
• Filtration: appropriate mesh filter to remove extraneous particles from molten mass; selectivity must be validated
• Packaging (cooling tower): cooling rate determines brittleness; too fast cooling = brittle suppositories
• Novel FFS technology (Form-Fill-Seal): thermoplastic sheets (PVC, polyethylene, Al foil laminates) serve as both molds and finished package; continuous process that eliminates older method problems

---

17. Reasons for Scale-Up Failures

• Scaling based on wrong unit operation mechanism
• Incompletely characterized equipment
• Insufficient process knowledge
• Use of different equipment types at different scale levels
• Unrealistic expectations
• Changes in product or process during scale-up

---

Summary Table: Product Attributes Evaluated During Scale-Up

---